56% seeking equipment & reagents, 54% lacking consumables... Southwest biomedical procurement needs revealed! Connect precisely with BPD Chengdu.

With Sichuan's comprehensive acceleration of reimbursement policies for innovative drugs, the Chengdu biopharmaceutical industry scale has surpassed 4000 billion yuan.The southwestern region is entering a peak period for biopharmaceutical capacity expansion, triggering concentrated demand across the entire industry chain.

2026BPD Chengdu Biopharmaceutical Process Development Conferencewill be11 5-6InHyatt Place Chengdu Bio-CityGrand opening. Based on the data collected during the pre-conference backend phase.Effective procurement demand in Southwest ChinaPurchase requirement graph clearly presented:Laboratory Equipment、Raw ReagentsDemand distribution by category56.4%，ConsumablesDemand Share53.8%Three major categories form the core of Southwest procurement.CRO/CDMO ServicesDemand Share38.5%，Construction EngineeringDemand Share5.1%。

Southwest China's biopharmaceutical sector is entering a critical window for capacity expansion, technical upgrades, and strengthening the entire value chain.2026BPD Chengdu offers an excellent opportunity for upstream and downstream companies to access the growing Southwest market!

Unlock demand across the entire value chain

Clear signal of industrial expansion

Current2026BPDChengduCovered purchase requisitionsLaboratory Equipment、Raw Reagents、Consumables、CRO/CDMO、Construction Engineeringand other diverse categories,Establish a full industry chain demand pattern spanning from front-end development to commercial production.。

Notably, bundled procurement is becoming the norm—33.3% of purchasing requests select all three categories: "Instruments," "Reagents," and "Consumables."Indicates that Southwest buyers are making a one-time configuration for the entire production line or laboratory.This procurement model means exhibitors will faceDecision-makers with a clear budget and a complete procurement list。

Against this backdrop,2026BPD Chengdu Biopharmaceutical Process Development Conferencewill be11 5-6InHyatt Place Chengdu Bio-CityGrandly hosted, bringing together2000+Professional Buyers,70+Featuring keynote speakers and a wide range of high-quality exhibitors, we provide an efficient platform focused on professional depth and practical solutions to industry pain points.

Exhibit now to connect precisely with Southwest buyers and potential clients who have clear procurement needs through BPD Chengdu Exhibition.Shorten the time from initial contact to deal closure.

• Accurate and genuine requirements:A surge of actionable, real-world procurement demands across three key categories—lab instruments, raw materials/reagents, and consumables—each accounting for over 50% of total demand. This offers enterprises an efficient pathway to quickly enter the growing Southwest China market.

• Decision-makers gathered:Procurement decision-makers from pharmaceutical companies, CDMOs, and research institutions in Southwest China will attend to discuss process requirements and selection solutions face-to-face.

• Precise time window:This means,
  
  

Policy-triggered enforcement

Leading in High Demand for Equipment and Raw Materials

A closer look at the procurement requests collected in Chengdu 2026BPD reveals that each one closely aligns with development opportunities in Southwest China.Demand for raw materials and reagents, as well as laboratory equipment, has risen sharply, driven by mandatory policy initiatives in the southwest region's biomedicine sector.

Sichuan Province issued 21 measures at the end of 2025, requiring that pharmacy and therapeutics committee meetings be held within 1 months after the release of the innovative drug and medical device catalog.Complete procurement by ensuring all required items are allocated.Pharmaceutical companies are expanding production capacity and preparing for scale-up, with new GMP workshops, pilot platforms, and quality control laboratories being launched simultaneously.Directly drives rigid procurement of equipment such as bioreactors, purification systems, lyophilizers, and analytical instruments., while driving the steady consumption of cell culture media, diagnostic reagents, and excipients for biopharmaceuticals. Chengdu Tianfu International Bio-City has attracted over 300 projects with a total committed investment exceeding 1400 billion yuan.The continued advancement of these companies' pipelines will drive ongoing equipment and reagent orders.

Rising proportion of consumables demand

Dual-pull R&D and production

2026BPD Southwest procurement requirements collected in Chengdu,Consumable demand share: 53.8%, core originates fromSouthwest R&D ClusterandProduction SideSynchronous scaling.

Chengdu Medical City has attracted over 650 enterprises, generating annual industrial revenue of 223 billion yuan in 2025. Kelun-Biotech has secured three ADC collaborations with Merck since 2022, with total upfront payments of 1.75 billion USD and potential milestone payments reaching up to 93 billion USD. Bailitianheng's bispecific ADC partnership with BMS has a potential total value of 84 billion USD.Pipeline advancementdriving increased consumption of single-use bioprocessing bags, purification filter capsules, and chromatography resins;GMP facility launchThis will drive bulk procurement of cleanroom consumables and sterile filling consumables.

As a result, consumables are one of the most widely covered and frequently repurchased categories in procurement demand across Southwest China.

CRO/CDMO demand exceeds one-third

Outsourced services accelerate penetration

Meanwhile,38.5% of CRO/CDMO procurement demand in Southwest Chinaindicates a heavy reliance of Southwest pharmaceutical companies on outsourcing their international pipeline development.

Multiple ADC licensing collaborations between Kelun-Biotech and Merck, as well as the global strategic partnership on bispecific ADCs between Baili Tianheng and BMS.Advancing the internationalization pipelineThere is a sustained demand for outsourced services in CMC development, process characterization, and quality research. Additionally,SME BiotechOutsourcing process development and analytical testing is becoming increasingly common. CRO/CDMO services have shifted from an option to a necessity.

Only 5 booths remaining. Book now!